ESR1 and breast carcinoma: Indeed, a retrospective study of 896 cases of breast cancer patients revealed that 40% cases of ERα-positive breast cancers expressed ERα-36, and those patients were less inclined to benefit from tamoxifen therapy.16 Moreover, 40% of ERα-negative breast cancers, while lacking ERα expression, expressed ERα-36.